Brokerages Set Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) PT at $77.08

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has earned a consensus recommendation of “Buy” from the sixteen analysts that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $75.93.

A number of research analysts have recently commented on the company. BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, July 23rd. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $73.00 target price on the stock in a report on Tuesday, April 23rd. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $83.00 to $79.00 and set an “overweight” rating on the stock in a report on Friday. Barclays reaffirmed a “buy” rating and set a $87.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Sunday. Finally, JPMorgan Chase & Co. reissued a “buy” rating and issued a $75.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Monday.

Shares of NASDAQ RARE traded down $1.74 during trading hours on Wednesday, hitting $53.92. The stock had a trading volume of 9,780 shares, compared to its average volume of 440,652. The firm has a market capitalization of $3.20 billion, a P/E ratio of -7.16 and a beta of 2.17. The company’s 50-day moving average price is $60.73. Ultragenyx Pharmaceutical has a 52 week low of $37.44 and a 52 week high of $90.98. The company has a quick ratio of 11.60, a current ratio of 11.77 and a debt-to-equity ratio of 0.03.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. The business had revenue of $24.15 million during the quarter, compared to analysts’ expectations of $22.16 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.66% and a negative net margin of 527.49%. The firm’s quarterly revenue was up 88.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.06) EPS. Equities research analysts anticipate that Ultragenyx Pharmaceutical will post -6.96 earnings per share for the current fiscal year.

In related news, EVP Karah Herdman Parschauer sold 1,226 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $61.50, for a total value of $75,399.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 7.80% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Ultragenyx Pharmaceutical by 6.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,325 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 212 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Ultragenyx Pharmaceutical by 8.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,113 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 242 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in Ultragenyx Pharmaceutical by 19.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,303 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 379 shares during the period. Meeder Asset Management Inc. boosted its holdings in Ultragenyx Pharmaceutical by 321.1% in the 1st quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 456 shares during the period. Finally, First Mercantile Trust Co. lifted its stake in Ultragenyx Pharmaceutical by 101.0% in the 1st quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 495 shares in the last quarter.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

See Also: How Do Front-End Loads Impact an Investment?

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.